AstraZeneca.
British-Swedish pharmaceutical company
- Reports this week
- 10
- Active events
- 13
- Connections
- 754
What's happening
Active this week
-
AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Some support3 reports
-
Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Well supported4 reports12 developments inside
-
AstraZeneca, AMPATH, and Lancet Laboratories launched the Helix Project in South Africa for advanced genomic testing.Some support1 report
-
AstraZeneca supplies HVO to EcoCeres for manufacturing backup power.Some support1 report
-
Collaboration between IONQ, AstraZeneca, and Amazon demonstrates quantum-accelerated chemistry workflow using AWS infrastructure.Well supported3 reports1 development inside
-
Nvidia, IonQ, AstraZeneca, and AWS are partnering to demonstrate advanced computing workflows using a standard CPU.Some support1 report
-
Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.Some support1 report
-
Both the Netherlands and AstraZeneca were discussed as potential undervalued international investments.Some support1 report
-
Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.Some support1 report1 development inside
-
AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.Some support2 reports
-
The NHS in England has cleared Enhertu for use, strengthening its access and availability.Some support2 reports
-
AstraZeneca is supporting a food access initiative taking place in Queens.Some support1 report
-
Oklahoma State Law seeks to expand patient access to discounted drugs and faces lawsuits challenging the 340B program scope.Some support2 reports
Earlier this month
-
Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.Some support2 reports1 development inside
-
Unpaid bills totaling R1bn are causing service suspensions in the Eastern Cape, affecting operations of AstraZeneca and Sandoz.Some support1 report
-
Tempus AI has named AstraZeneca as a customer, and Morgan Stanley boosted its revenue outlook.Some support2 reports
-
Analysts are monitoring the performance and pipeline risks of AstraZeneca, following concurrent stake purchases and increased holdings by Bank of America.Some support1 report1 development inside
-
AstraZeneca announced a major €26 billion investment in Wuxi, China, while simultaneously facing an underperform rating and tracking global oil prices.Some support1 report
-
AstraZeneca is supplying a nasal spray vaccine to Ireland.Some support1 report
-
A drug status update affecting Australian patients involves Ipsen and AstraZeneca, with changes made to the Pharmaceutical Benefits Scheme (PBS) on September 1, 2026.Some support1 report
-
Amit Shah oversaw anti-terror operations in Jammu and Kashmir, while simultaneously, an investment upgraded production bases in Wuxi.Some support1 report
-
Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.Some support3 reports4 developments inside
-
AstraZeneca's drug was tested in collaboration with Pfizer's drug.Some support1 report
-
AstraZeneca is facing market pressure following a clinical trial failure, leading to a decline in its stock value.Some support1 report1 development inside
-
Following AstraZeneca's clinical trial failure, investor sentiment has turned negative, leading Stifel to cut the price target for Olema Pharmaceuticals.Some support1 report
-
Ayala Healthcare Holdings Inc. and Healthway Medical Network partner with AstraZeneca to strengthen clinical trial capabilities in Metro Manila.Some support1 report
-
Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.Some support2 reports
-
AstraZeneca and Innate Pharma S.A. are collaborating on developing a lead pharmaceutical program.Some support1 report
-
Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.Some support2 reports
-
AstraZeneca and Dell EMC are both employing senior leadership roles within their Human Resources departments.Some support1 report
-
AstraZeneca leveraged an investigator's assessment regarding the clinical benefit of its treatments.Some support1 report
-
Petra Hamerlik, who previously worked at AstraZeneca plc, has been appointed as the Chair of Translational Neuro-Oncology at the University of Manchester.Some support1 report
-
Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.Some support3 reports1 development inside
-
Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.Some support2 reports
-
Amgen and AstraZeneca announced a collaborative development of a combination therapy.Some support2 reports1 development inside
-
Joint drug trial success boosts Amgen stock.Some support1 report
-
AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.Some support1 report2 developments inside
-
AstraZeneca and GSK, along with Aurora Cannabis Inc., are involved in hiring Faris El Refaie for global commercial leadership, gaining experience in the pharmaceutical sector.Some support3 reports
-
Cramer provided market sentiment and investment advice regarding company trials involving AstraZeneca and Trinity Industries.Some support1 report
-
AstraZeneca and Novavax are pursuing technology transfer to enable local vaccine production.Some support1 report
-
George Godfrey, formerly of AstraZeneca, has been appointed Senior Director at Novo Nordisk.Some support1 report
-
AstraZeneca released a press release citing Dr. Frank Sciurba.Some support6 reports
-
Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.Well supported4 reports
-
FDA granted accelerated approval for Etcamah combination therapy after trial results were presented at ASCO.Some support5 reports
-
Geopolitical instability in the Middle East has led to significant corporate fallout, including the cancellation of Flutter's London Stock Exchange listing and AstraZeneca considering a move to the US market.Some support1 report
-
Executives from Carlsberg, Lloyds Banking Group, Diageo, and AstraZeneca attended an AI Impact Summit in London.Some support1 report1 development inside
One to three months ago
-
Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.Some support1 report
-
Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.Some support1 report
-
AstraZeneca plans its largest manufacturing investment in Virginia, reported from Cambridge.Some support2 reports1 development inside
-
AstraZeneca is investing $4.5 billion in a new manufacturing campus near Charlottesville, Virginia.Some support2 reports
-
Goldman Sachs and Morgan Stanley engaged in joint book-running management of a bond issuance for AstraZeneca.Some support2 reports
-
A clinical trial comparing volrustomig against Keytruda was reported, alongside news that Union Investment is an AstraZeneca shareholder.Some support1 report1 development inside
-
AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.Some support1 report
-
Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.Well supported32 reports3 developments inside
-
AstraZeneca and Sachi are collaborating on trials for Non-Small Cell Lung Cancer (NSCLC), with the results of the Saffron trial potentially leading to U.S. approval.Some support1 report
-
AstraZeneca announced a joint development and commercialization partnership with HUTCHMED, a company based in China with operations in Shanghai.Some support1 report2 developments inside
-
Cavendish acted as broker for Hutchmed trials combining Savolitinib with AstraZeneca's Tagrisso.Some support2 reports
-
AstraZeneca acquired Fusion Pharmaceuticals for approximately US$2 billion in 2024.Some support1 report
-
Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.Some support3 reports1 development inside
-
Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.Some support3 reports
No events began in the chosen period. Widen it, or reset.
What's reaching AstraZeneca
Recent events traced to AstraZeneca, step by stepAround AstraZeneca this week
News at the entities that move AstraZeneca most-
Bristol-Myers Squibb TransactionalBristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Moves AstraZeneca
-
Daiichi Sankyo StructuralThe Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.Moves AstraZeneca
-
Ionis Pharmaceuticals TransactionalGSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.Moves AstraZeneca
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves AstraZeneca
-
London Stock Exchange StructuralQinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.Moves AstraZeneca
-
European Medicines Agency StructuralBoth the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Moves AstraZeneca
Connections
The 40 strongest of 754, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Bristol-Myers Squibb Transactional
The two pharmaceutical companies are engaged in high-stakes merger talks regarding a potential combined entity valued at approximately $400 billion.
-
Daiichi Sankyo Structural
The companies are engaged in a deep, ongoing partnership for the joint development and commercialization of advanced cancer treatments, including Enhertu and Datroway.
-
Ionis Pharmaceuticals Transactional
The companies formed a joint development partnership for the Wainua gene-silencing drug candidate, which ultimately failed in late-stage clinical trials.
-
Pascal Soriot Structural
Pascal Soriot holds the executive leadership role as CEO of AstraZeneca.
-
Tempus Operational
Tempus and AstraZeneca are engaged in a partnership to jointly develop an oncology foundation model, supported by a $200M data licensing deal.
-
Compugen Ltd. Structural
Compugen licenses technology and antibodies to AstraZeneca, enabling the development of the drug Rilvegostomig.
-
AbbVie Operational
AbbVie and AstraZeneca are direct competitors in oncology and dyslipidemia, while also engaging in strategic collaborations, such as AI initiatives.
-
FDA Structural
The FDA acts as the necessary regulatory body, evaluating submissions and granting market access for AstraZeneca's products.
Show all 40 connections
-
FibroGen (United States) Transactional
AstraZeneca acquired FibroGen China and its assets through a series of sales and acquisitions.
-
Pfizer Operational
Pfizer and AstraZeneca are active competitors in major biopharma markets, including oncology and functional dyspepsia.
-
London Stock Exchange Structural
AstraZeneca is formally listed on the London Stock Exchange, making the exchange critical for its valuation and market operations.
-
Albemarle County Structural
AstraZeneca is establishing a major manufacturing campus in Albemarle County with a secured investment of $4.5 billion.
-
Daiichi Sankyo (United Kingdom) Operational
AstraZeneca and Daiichi Sankyo maintain a formal partnership and licensing agreement for the drug Enhertu.
-
Morgan Stanley Operational
Morgan Stanley provides financial ratings, stock advice, and investment banking services for AstraZeneca.
-
Frank Sciurba Structural
Frank Sciurba serves as the Chief Investigator for AstraZeneca's LUNA programme, linking his expertise to the company's research announcements.
-
Merck Operational
AstraZeneca and Merck actively compete in the oncology space while simultaneously engaging in strategic partnerships and profit-sharing agreements.
-
Hutchison MediPharma Limited Structural
AstraZeneca and Hutchison MediPharma are engaged in a formal joint development and commercialization partnership for the drug savolitinib.
-
Alnylam Pharmaceuticals Operational
The companies are direct competitors in the ATTR-CM indication while also maintaining a formal partnership on drug development.
-
GSK Operational
GSK and AstraZeneca are direct competitors in the pharmaceutical market, facing rivalry in oncology and respiratory sectors.
-
Eli Lilly and Company Operational
Eli Lilly and AstraZeneca are active competitors in the pharmaceutical market, vying for market share in oncology and obesity.
-
Sanofi Operational
Sanofi and AstraZeneca are actively collaborating on the production and scaling of the drug Beyfortus.
-
Daiichi Operational
AstraZeneca and Daiichi are engaged in a formal partnership for joint drug development and marketing.
-
Fusion Pharmaceuticals Structural
Fusion Pharmaceuticals was acquired by AstraZeneca in 2024 for approximately US$2 billion.
-
European Medicines Agency Structural
The European Medicines Agency reviews AstraZeneca's products for market approval.
-
Union Investment Structural
Union Investment is a current shareholder in AstraZeneca, creating a dependency structure.
-
American Society of Clinical Oncology Operational
AstraZeneca utilizes the ASCO Annual Meeting as a platform for presenting clinical trial results and engaging with the oncology scientific community.
-
Johnson & Johnson Operational
Johnson & Johnson and AstraZeneca are major pharmaceutical companies engaged in direct competition within the oncology and immunology markets.
-
IONQ Operational
IONQ and AstraZeneca maintain an active partnership focused on leveraging quantum computing for accelerating drug discovery and computational chemistry workflows.
-
CSPC Pharmaceutical Group Operational
AstraZeneca and CSPC are actively collaborating on AI drug discovery and experimental treatments for chronic diseases, including kidney disease.
-
Sophia Genetics Operational
AstraZeneca and Sophia Genetics have formed a multi-year partnership to leverage AI for breast cancer therapies.
-
Novo Nordisk Operational
The two companies are direct, active competitors, specifically challenging each other in the obesity drug market.
-
London Operational
AstraZeneca is headquartered in London, and its corporate and stock market activities directly influence the city's financial ecosystem.
-
Biogen Operational
The two companies are actively competing in the market, facing pressure to meet ambitious revenue targets.
-
SEC Structural
AstraZeneca is subject to financial reporting and regulatory oversight by the SEC.
-
Court of Justice of the European Union Structural
AstraZeneca operates as a company subject to the jurisdiction, rulings, and oversight of the Court of Justice of the European Union.
-
Edge Structural
Edge was employed as a scientist at AstraZeneca.
-
Amundi Transactional
Amundi increased its financial holdings and stake in AstraZeneca shares.
-
Hoffmann-La Roche Operational
Hoffmann-La Roche and AstraZeneca are direct competitors in the pharmaceutical market, facing shared market pressures and rivalry in drug development.
-
Danaher Corporation Operational
Danaher and AstraZeneca maintain a formal partnership focused on developing and scaling precision medicine diagnostics.
-
Summit Therapeutics Transactional
AstraZeneca is actively negotiating and partnering with Summit Therapeutics regarding lung cancer drug development and licensing.
History
Events by the month they beganSeptember 2026
37 events- AstraZeneca, AMPATH, and Lancet Laboratories launched the Helix Project in South Africa for advanced genomic testing.
- AstraZeneca supplies HVO to EcoCeres for manufacturing backup power.
- Nvidia, IonQ, AstraZeneca, and AWS are partnering to demonstrate advanced computing workflows using a standard CPU.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.
- Both the Netherlands and AstraZeneca were discussed as potential undervalued international investments.
- Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
- AbbVie, AstraZeneca, and Bristol-Myers Squibb collaborated on the AISB Bind AI initiative.
- The NHS in England has cleared Enhertu for use, strengthening its access and availability.
- AstraZeneca is supporting a food access initiative taking place in Queens.
- Oklahoma State Law seeks to expand patient access to discounted drugs and faces lawsuits challenging the 340B program scope.
- Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.
- Unpaid bills totaling R1bn are causing service suspensions in the Eastern Cape, affecting operations of AstraZeneca and Sandoz.
- Tempus AI has named AstraZeneca as a customer, and Morgan Stanley boosted its revenue outlook.
- AstraZeneca announced a major €26 billion investment in Wuxi, China, while simultaneously facing an underperform rating and tracking global oil prices.
- AstraZeneca is supplying a nasal spray vaccine to Ireland.
- A drug status update affecting Australian patients involves Ipsen and AstraZeneca, with changes made to the Pharmaceutical Benefits Scheme (PBS) on September 1, 2026.
- Amit Shah oversaw anti-terror operations in Jammu and Kashmir, while simultaneously, an investment upgraded production bases in Wuxi.
- AstraZeneca's drug was tested in collaboration with Pfizer's drug.
- Following AstraZeneca's clinical trial failure, investor sentiment has turned negative, leading Stifel to cut the price target for Olema Pharmaceuticals.
- Ayala Healthcare Holdings Inc. and Healthway Medical Network partner with AstraZeneca to strengthen clinical trial capabilities in Metro Manila.
- Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.
- AstraZeneca and Innate Pharma S.A. are collaborating on developing a lead pharmaceutical program.
- Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.
- AstraZeneca and Dell EMC are both employing senior leadership roles within their Human Resources departments.
- AstraZeneca leveraged an investigator's assessment regarding the clinical benefit of its treatments.
- Petra Hamerlik, who previously worked at AstraZeneca plc, has been appointed as the Chair of Translational Neuro-Oncology at the University of Manchester.
- Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.
- Amgen and AstraZeneca announced a collaborative development of a combination therapy.
- Joint drug trial success boosts Amgen stock.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- AstraZeneca and GSK, along with Aurora Cannabis Inc., are involved in hiring Faris El Refaie for global commercial leadership, gaining experience in the pharmaceutical sector.
- Cramer provided market sentiment and investment advice regarding company trials involving AstraZeneca and Trinity Industries.
- AstraZeneca and Novavax are pursuing technology transfer to enable local vaccine production.
- George Godfrey, formerly of AstraZeneca, has been appointed Senior Director at Novo Nordisk.
- AstraZeneca released a press release citing Dr. Frank Sciurba.
- FDA granted accelerated approval for Etcamah combination therapy after trial results were presented at ASCO.
- Geopolitical instability in the Middle East has led to significant corporate fallout, including the cancellation of Flutter's London Stock Exchange listing and AstraZeneca considering a move to the US market.
August 2026
14 events- Analysts are monitoring the performance and pipeline risks of AstraZeneca, following concurrent stake purchases and increased holdings by Bank of America.
- Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.
- Executives from Carlsberg, Lloyds Banking Group, Diageo, and AstraZeneca attended an AI Impact Summit in London.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Hoffmann-La Roche, AstraZeneca, and Pfizer are participating in local pharmaceutical production projects in Kazakhstan.
- AstraZeneca is investing $4.5 billion in a new manufacturing campus near Charlottesville, Virginia.
- Goldman Sachs and Morgan Stanley engaged in joint book-running management of a bond issuance for AstraZeneca.
- A clinical trial comparing volrustomig against Keytruda was reported, alongside news that Union Investment is an AstraZeneca shareholder.
- AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.
- Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.
- AstraZeneca and Sachi are collaborating on trials for Non-Small Cell Lung Cancer (NSCLC), with the results of the Saffron trial potentially leading to U.S. approval.
- Cavendish acted as broker for Hutchmed trials combining Savolitinib with AstraZeneca's Tagrisso.
- AstraZeneca acquired Fusion Pharmaceuticals for approximately US$2 billion in 2024.
- Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.
July 2026
3 events- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- AstraZeneca is facing market pressure following a clinical trial failure, leading to a decline in its stock value.
- Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.
Show 1 earlier month
June 2026
6 events- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.
- Collaboration between IONQ, AstraZeneca, and Amazon demonstrates quantum-accelerated chemistry workflow using AWS infrastructure.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- AstraZeneca plans its largest manufacturing investment in Virginia, reported from Cambridge.
- AstraZeneca announced a joint development and commercialization partnership with HUTCHMED, a company based in China with operations in Shanghai.
- Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.